Melanoma
Showing NaN - NaN of 71
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)
Recruiting
- Small Cell Lung Cancer
- +8 more
- ladiratuzumab vedotin
- pembrolizumab
-
Chandler, Arizona
- +65 more
Dec 19, 2022
Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)
Recruiting
- Melanoma
- Nivolumab
- Nivolumab + Relatlimab Fixed Dose Combination
-
Birmingham, Alabama
- +185 more
Dec 3, 2022
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)
Completed
- Melanoma
- +27 more
- XmAb20717
-
Los Angeles, California
- +16 more
Nov 29, 2022
Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)
Terminated
- Melanoma
- Talimogene Laherparepvec
- +2 more
-
Birmingham, Alabama
- +160 more
Nov 10, 2022
Melanoma Trial in Worldwide (Pembrolizumab, Placebo)
Active, not recruiting
- Melanoma
- Pembrolizumab
- Placebo
-
Tucson, Arizona
- +158 more
Oct 31, 2022
Melanoma, Ocular Melanoma Trial in United States (Nivolumab, Ipilimumab)
Active, not recruiting
- Melanoma
- Ocular Melanoma
-
San Francisco, California
- +5 more
Aug 31, 2022
Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)
Active, not recruiting
- Melanoma
- mRNA-4157
- Pembrolizumab
-
Tucson, Arizona
- +21 more
Aug 23, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Melanoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in United States (GEN-011, IL-2, Fludarabine)
Terminated
- Melanoma
- +8 more
- GEN-011
- +3 more
-
Gilbert, Arizona
- +7 more
Jul 13, 2022
Melanoma Trial in Worldwide (Relatlimab, Nivolumab)
Active, not recruiting
- Melanoma
- Relatlimab
- Nivolumab
-
Tucson, Arizona
- +126 more
Mar 2, 2022
Melanoma, Carcinoma, Non-Small- Cell Lung Trial in Worldwide (SEA-CD40, pembrolizumab, pemetrexed)
Recruiting
- Melanoma
- Carcinoma, Non-Small- Cell Lung
- SEA-CD40
- +3 more
-
Springdale, Arkansas
- +18 more
Mar 11, 2022
Melanoma Trial in France, Germany, United States (Talimogene laherparepvec, Ipilimumab)
Melanoma Trial in United States (MGA271)
Terminated
- Melanoma
- MGA271
-
Los Angeles, California
- +6 more
Feb 4, 2022
Melanoma, Non Small Cell Lung Cancer Trial in United States (enoblituzumab plus ipilimumab)
Completed
- Melanoma
- Non Small Cell Lung Cancer
- enoblituzumab plus ipilimumab
-
Los Angeles, California
- +9 more
Feb 4, 2022
Prostate Cancer, Melanoma, Renal Cell Carcinoma Trial in United States (MGA271)
Completed
- Prostate Cancer
- +6 more
- MGA271
-
Los Angeles, California
- +11 more
Feb 4, 2022
Testing Practices for Common Solid Cancers in Precision Oncology
Active, not recruiting
- Breast Carcinoma
- +5 more
- Survey Administration
-
Chicago, IllinoisCenter for Business Models in Healthcare
Dec 29, 2021
Melanoma Trial in Chicago (SSE educational intervention, Active control:Healthy Living)
Completed
- Melanoma
- SSE educational intervention
- Active control:Healthy Living
-
Chicago, IllinoisNorthwestern University Feinberg School of Medicine Department o
Nov 19, 2021
Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly
Completed
- Cutaneous Melanoma
- +11 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +2 more
-
Chicago, Illinois
- +6 more
Nov 10, 2021